


BTLA

Anti-BTLA Products
- Human Anti-BTLA Recombinant Antibody (TAB-1310CL) (TAB-1310CL)
-
- Species Reactivity: Cynomolgus, Human
- Type: Human IgG
- Application: Block
- Human Anti-BTLA Recombinant Antibody (TAB-1311CL) (TAB-1311CL)
-
- Species Reactivity: Cynomolgus, Human
- Type: Human IgG1
- Application: ELISA
- Human Anti-BTLA Recombinant Antibody; scFv Fragment (TAB-1309CL-S(P)) (TAB-1309CL-S(P))
-
- Species Reactivity: Cynomolgus, Human
- Type: Human scFv
- Application: ELISA
- Human Anti-BTLA Recombinant Antibody; scFv Fragment (TAB-1310CL-S(P)) (TAB-1310CL-S(P))
-
- Species Reactivity: Cynomolgus, Human
- Type: Human scFv
- Application: ELISA
- Human Anti-BTLA Recombinant Antibody; scFv Fragment (TAB-1311CL-S(P)) (TAB-1311CL-S(P))
-
- Species Reactivity: Cynomolgus, Human
- Type: Human scFv
- Application: ELISA
- Human Anti-BTLA Recombinant Antibody; Fab Fragment (TAB-1309CL-F(E)) (TAB-1309CL-F(E))
-
- Species Reactivity: Cynomolgus, Human
- Type: Human Fab
- Application: ELISA
- Human Anti-BTLA Recombinant Antibody; Fab Fragment (TAB-1310CL-F(E)) (TAB-1310CL-F(E))
-
- Species Reactivity: Cynomolgus, Human
- Type: Human Fab
- Application: ELISA
- Human Anti-BTLA Recombinant Antibody; Fab Fragment (TAB-1311CL-F(E)) (TAB-1311CL-F(E))
-
- Species Reactivity: Cynomolgus, Human
- Type: Human Fab
- Application: ELISA
- Anti-Human BTLA Recombinant Antibody (TAB-076CL)
-
- Derivation: Human
- Species Reactivity: Human
- Type: Antibody
- Human Anti-BTLA Recombinant Antibody (TAB-1309CL) (TAB-1309CL)
-
- Species Reactivity: Cynomolgus, Human
- Type: Human IgG
- Application: Inhib
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs offers a comprehensive range of anti-BTLA recombinant antibodies, engineered to deliver exceptional specificity and affinity for cutting-edge immunological research and therapeutic development. Our products undergo rigorous validation to ensure optimal performance across diverse assays, providing researchers with the precision and reliability required for their critical studies.
BTLA: An Attractive Target for Cancer Therapy
The B and T lymphocyte attenuator (BTLA) is a critical cosignaling molecule within the CD28 superfamily, sharing structural and functional similarities with PD-1 and CTLA-4. BTLA is expressed in most lymphocytes and plays a key role in immune regulation by inhibiting the activation and proliferation of B and T cells. Recent research has highlighted BTLA’s involvement in a variety of pathological processes, including cancer, inflammatory diseases, autoimmune disorders, infectious diseases, and transplant rejection. Consequently, the development of antibodies targeting BTLA presents a promising avenue for cancer treatment.
Alternative Names
B And T Lymphocyte Associated; B- And T-Lymphocyte-Associated Protein; B- And T-Lymphocyte Attenuator; CD272 Antigen; BTLA1; CD272.
Background
This gene encodes a member of the immunoglobulin superfamily. The encoded protein contains a single immunoglobulin (Ig) domain and is a receptor that relays inhibitory signals to suppress the immune response. Alternative splicing results in multiple transcript variants. Polymorphisms in this gene have been associated with an increased risk of rheumatoid arthritis.
CD markers
Intracellular, Membrane (different isoforms)
Cell type enriched (B-cells)
Group enriched (naive B-cell, memory B-cell, plasmacytoid DC)
Cell line enhanced (U-698)
Interacts with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2 (PubMed:12796776, PubMed:14652006). Interacts with TNFRSF14/HVEM (via cysteine-rich domain 1) (PubMed:15568026, PubMed:18193050, PubMed:19915044).
Receptor
Anti-BTLA rAb Products
Creative Biolabs offers a comprehensive selection of anti-BTLA recombinant antibodies designed to specifically target and inhibit BTLA. These high-quality antibodies are characterized by their exceptional affinity and specificity, ensuring precise binding and inhibition. Available in various formats to meet diverse research needs, our anti-BTLA antibodies are ideal for a wide range of immunological studies.
Table 1. Featured anti-BTLA recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
HPAB-1605LY | Human Anti-BTLA Recombinant Antibody | Human | Humanized IgG | ELISA, FC |
HPAB-M0448-YC | Mouse Anti-BTLA Recombinant Antibody | Human | Mouse IgG | FC |
HPAB-0196-WJ | Mouse Anti-BTLA Recombinant Antibody | Human | Mouse IgG1 | ELISA, FC, WB, Neut |
TAB-1309CL | Human Anti-BTLA Recombinant Antibody | Cynomolgus, Human | Human IgG | Inhib |
TAB-1310CL | Human Anti-BTLA Recombinant Antibody | Cynomolgus, Human | Human IgG | Block |
Creative Quality Control
Creative Biolabs is dedicated to providing premium anti-BTLA recombinant antibodies for cutting-edge immunological research. Our advanced facilities and stringent quality assurance protocols guarantee the creation of antibodies that possess superior characteristics. At the same time, our dedicated scientific team actively oversees and refines our production methods to uphold the utmost standards in biotechnological innovation.
Fig.1 SDS-PAGE analysis of anti-BTLA antibody
(Cat# TAB-1310CL, Creative Biolabs).
Fig.2 HPLC analysis of anti-BTLA antibody
(Cat# TAB-1310CL, Creative Biolabs).
Fig.3 SDS-PAGE analysis of anti-BTLA antibody
(Cat# TAB-1309CL, Creative Biolabs).
Customer Reviews

Mouse Anti-BTLA Recombinant Antibody (HPAB-M0448-YC) (HPAB-M0448-YC)

Human Anti-BTLA Recombinant Antibody (HPAB-1605LY) (HPAB-1605LY)

Mouse Anti-BTLA Recombinant Antibody (HPAB-0194-WJ) (HPAB-0194-WJ)
rAb Production
Our state-of-the-art anti-BTLA recombinant antibody platform leverages genetically modified cells to generate high-quality antibodies specifically targeting the BTLA protein. This innovative system facilitates scalable and efficient production, providing a reliable supply for both research and therapeutic uses.
Featured Anti-BTLA Recombinant Antibody Production Platforms
Fig.4 Milligram-scale anti-BTLA recombinant antibody production.
Fig.5 Gram-scale anti-BTLA recombinant antibody production.
rAb Modalities
Creative Biolabs provides an extensive selection of premium anti-BTLA recombinant antibodies in multiple formats.
Fig.6 Full-length anti-BTLA recombinant antibody production and modalities.
BTLA-Targeted Drug Information
Table 2. Public drug targeting BTLA.
Highest Phase | Mechanism of Action | Product Category | Condition | Organization |
Phase III |
Anti-BTLA (B- and T-lymphocyte Attenuator) Immune Checkpoint Inhibitors |
Cancer Immunotherapy Humanized Monoclonal Antibodies |
Cancer, head and neck (squamous cell carcinoma) Cancer, lung Cancer, lung (non-small cell) (NSCLC) Cancer, lung (small cell) (SCLC) (extensive) Cancer, lung (small cell) (SCLC) (limited) Cancer, nasopharynx Cancer, solid tumor Hodgkin lymphoma (classical) Lymphoma |
Shanghai Junshi Biosciences (Originator) |
Phase II |
Anti-BTLA (B- and T-lymphocyte Attenuator) Immune Checkpoint Inhibitors |
Antibodies |
Atopic dermatitis Inflammatory disorders |
AnaptysBio (Originator) |
Phase I |
Anti-BTLA (B- and T-lymphocyte Attenuator) B- and T-Lymphocyte Attenuator (BTLA) Activators Immune Checkpoint Inhibitors |
Agonist Antibodies |
Autoimmune disease Rheumatoid arthritis Systemic lupus erythematosus |
Gilead (Originator) |
Discontinued |
Anti-BTLA (B- and T-lymphocyte Attenuator) Immune Checkpoint Inhibitors |
Agonist Antibodies Monoclonal Antibodies |
Inflammatory disorders Plaque psoriasis Psoriasis Rheumatoid arthritis Systemic lupus erythematosus |
Lilly (Originator) |
Preclinical | B- and T-Lymphocyte Attenuator (BTLA) Activators |
Fusion Proteins Polypeptides, from 41 AA |
Inflammatory disorders |
Avalo Therapeutics Sanford Burnham Prebys Medical Discovery Institute (Originator) |
Preclinical | Cell-Based Gene Therapy | Diabetes type 1 | Guiyang First People's Hospital (Originator) | |
Biological Testing | BTLA Expression Inhibitors |
CRISPR/Cas-Mediated Edited Cell Therapy Mesenchymal Stem Cells MicroRNA Oligoribonucleotide (RNA) Short Hairpin RNA (shRNA) |
Cancer, colorectal Cancer, liver (hepatocellular carcinoma) Melanoma |
Future Homo Sapiens Regenerative Medicine Research Institute (guangzhou) (Originator) |
Biological Testing |
Anti-BTLA (B- and T-lymphocyte Attenuator) Immune Checkpoint Inhibitors |
Antibodies Antibody Gene Therapy Cancer Immunotherapy CRISPR/Cas-Mediated Edited Cell Therapy Mesenchymal Stem Cells Stem Cell-Based Gene Therapy |
Cancer Cancer, colorectal Cancer, liver Melanoma |
Future Homo Sapiens Regenerative Medicine Research Institute (guangzhou) (Originator) |
Biological Testing | BTLA Expression Inhibitors |
RNA Interference Single-stranded oligoribonucleotide (RNA) |
Immunological Disorders | Shenzhen Biocan Technologies (Originator) |
Biological Testing | BTLA Expression Inhibitors |
Double-stranded oligoribonucleotide (RNA) Short Hairpin RNA (shRNA) |
Autoimmune disease Cancer Infections Transplant rejection |
Shenzhen Biocan Technologies (Originator) |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
Need a unique antibody tailored to your specific research needs? Please contact us to design and produce custom anti-BTLA antibodies to meet your exact requirements.